Cite
HARVARD Citation
Muik, A. et al. (n.d.). 561 DuoBody®-PD-L1×4–1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4–1BB co-stimulation. Journal for immunotherapy of cancer. p. A595. [Online].